Tags : ADC

Medicilon Assists Huaota's CD73-targeting ADC approved for clinical use in US

Medicilon Assists Huaota's CD73-targeting ADC appr..

A Story by Medicilon


Recently, Shanghai Huaota Biopharmaceutical Co., Ltd. (Huaota) received a notification from the US FDA, agreeing that the third-generation antibody dr..